Pricing Log in Create free account
Saturday 31 October 2026 Export AMGN’s income statement to Excel — free account

Amgen Inc.

AMGN Healthcare Drug Manufacturers General

Amgen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $36.8 billion, up 9.95% from fiscal 2024. In the quarter to June 2026, revenue grew 9.53%, EPS grew 65.4%, free cash flow grew 82.6% and total debt rose 1.96%, each against the same quarter a year earlier. Member of the S&P 500, Nasdaq 100 and Dow Jones; dividend growth for ten consecutive years, revenue growth for five.

466.16 5.43 +1.18%
Market cap
$249.1B
P/E
28.7×
Fwd P/E
29.6×
Dividend yield
2.67%
F-score
7/9
Altman Z
1.69
Beneish M
−2.27
Dividend safety
56/100
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Filings

Amgen Inc. 10-Q filed Aug 7, 2024

Fiscal Q2 2024 · Period ended Jun 30, 2024 · Filed · accepted 6:54 PM ET · Document on sec.gov · Filing index

Nothing in this filing raised a red flag. The document itself is on sec.gov.

Read the filing on sec.gov